Tumor-intrinsic oncogene pathways mediating immune avoidance

OncoImmunology

Volumn 5, Issue 3, 2016, Pages

  Spranger, Stefani ^a   Gajewski, Thomas F ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cancer immunotherapy; checkpoint blockade; non T cell inflamed tumor; T cell infiltration; T cell inflamed tumor; tumor immune evasion

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; B RAF KINASE; BETA CATENIN; CD103 ANTIGEN; CD8ALPHA ANTIGEN; COLONY STIMULATING FACTOR 1; CRE RECOMBINASE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOPHENOL MONOOXYGENASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN P53; RANTES; STAT3 PROTEIN; TAMOXIFEN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A;

CANCER INFILTRATION; CELL INFILTRATION; CYTOMEGALOVIRUS INFECTION; DENDRITIC CELL; EXOME; GENE DELETION; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LUNG CANCER; MACROPHAGE; MELANOMA; NONHUMAN; ONCOGENE; PHENOTYPE; REVIEW; TUMOR GROWTH; WNT SIGNALING PATHWAY;

EID: 84961674073     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1086862     Document Type: Review

References (51)

1. S.L.Topalian, F.S.Hodi, J.R.Brahmer, S.N.Gettinger, D.C.Smith, D.F.McDermott, J.D.Powderly, R.D.Carvajal, J.A.Sosman, M.B.Atkins et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
2. F.S.Hodi, S.J.O'Day, D.F.McDermott, R.W.Weber, J.A.Sosman, J.B.Haanen, R.Gonzalez, C.Robert, D.Schadendorf, J.C.Hassel et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
3. M.B.Fuertes, A.K.Kacha, J.Kline, S.R.Woo, D.M.Kranz, K.M.Murphy, T.F.Gajewski. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{α}+ dendritic cells. J Exp Med. 2011; 208:2005-16; PMID:21930765; http://dx.doi.org/10.1084/jem.20101159
4. O.Hamid, R.D.Carvajal. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. Expert Opin Biol Ther. 2013; 13:847-61; PMID:23421934; http://dx.doi.org/10.1517/14712598.2013.770836
5. J.Stagg, B.Allard. Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. Ther Adv Med Oncol. 2013; 5:169-81; PMID:23634195; http://dx.doi.org/10.1177/1758834012475152
6. M.S.Swanson, U.K.Sinha. Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer-review of current data. Oral Oncol. 2015; 51:12-5; PMID:25459157; http://dx.doi.org/10.1016/j.oraloncology.2014.10.010
7. H.Harlin, Y.Meng, A.C.Peterson, Y.Zha, M.Tretiakova, C.Slingluff, M.McKee, T.F.Gajewski. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 2009; 69:3077-85; PMID:19293190; http://dx.doi.org/10.1158/0008-5472.CAN-08-2281
8. S.Spranger, R.M.Spaapen, Y.Zha, J.Williams, Y.Meng, T.T.Ha, T.F.Gajewski. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013; 5:200ra116; PMID:23986400; http://dx.doi.org/10.1126/scitranslmed.3006504
9. T.F.Gajewski, J.Louahed, V.G.Brichard. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J. 2010; 16:399-403; PMID:20693853; http://dx.doi.org/10.1097/PPO.0b013e3181eacbd8
10. P.C.Tumeh, C.L.Harview, J.H.Yearley, I.P.Shintaku, E.J.Taylor, L.Robert, B.Chmielowski, M.Spasic, G.Henry, V.Ciobanu et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515:568-71; PMID:25428505; http://dx.doi.org/10.1038/nature13954
11. S.Spranger, H.Koblish, B.Horton, P.Scherle, R.Newton, T.Gajewski. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment. J Immunother Cancer. 2014; 2; PMID:24829760; shttp://dx.doi.org/10.1186/2051-1426-2-3
12. T.N.Schumacher, R.D.Schreiber. Neoantigens in cancer immunotherapy. Science 2015; 348:69-74; PMID:25838375; http://dx.doi.org/10.1126/science.aaa4971
13. A.Snyder, V.Makarov, T.Merghoub, J.Yuan, J.M.Zaretsky, A.Desrichard, L.A.Walsh, M.A.Postow, P.Wong, T.S.Ho et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371:2189-99; PMID:25409260; http://dx.doi.org/10.1056/NEJMoa1406498
14. N.A.Rizvi, M.D.Hellmann, A.Snyder, P.Kvistborg, V.Makarov, J.J.Havel, W.Lee, J.Yuan, P.Wong, T.S.Ho et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; PMID:25765070; http://dx.doi.org/10.1126/science.aaa1348
15. Gajewski T, Zha Y, Hernandez K, Li Y, Bao R, Alexieff P, Andrade J, Luke J, Spranger S. Density of immunogenic antigens and presence or absence of the T cell-inflamed tumor microenvironment in metastatic melanoma. Journal of Clinical Oncology, 2015 ASCO Annual Meeting (May 29 - June 2, 2015). Vol 33, No 15_suppl (May 20 Supplement), 2015; 3002
16. S.R.Woo, M.B.Fuertes, L.Corrales, S.Spranger, M.J.Furdyna, M.Y.Leung, R.Duggan, Y.Wang, G.N.Barber, K.A.Fitzgerald et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 2014; 41:830-42; PMID:25517615; http://dx.doi.org/10.1016/j.immuni.2014.10.017
17. B.T.Edelson, W.Kc, R.Juang, M.Kohyama, L.A.Benoit, P.A.Klekotka, C.Moon, J.C.Albring, W.Ise, D.G.Michael et al. Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8alpha+ conventional dendritic cells. J Exp Med. 2010; 207:823-36; PMID:20351058; http://dx.doi.org/10.1084/jem.20091627
18. J.J.Engelhardt, B.Boldajipour, P.Beemiller, P.Pandurangi, C.Sorensen, Z.Werb, M.Egeblad, M.F.Krummel. Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. Cancer Cell. 2012; 21:402-17; PMID:22439936; http://dx.doi.org/10.1016/j.ccr.2012.01.008
19. T.F.Gajewski, H.Schreiber, Y.X.Fu. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013; 14:1014-22; PMID:24048123; http://dx.doi.org/10.1038/ni.2703
20. L.Deng, H.Liang, B.Burnette, M.Beckett, T.Darga, R.R.Weichselbaum, Y.X.Fu. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014; 124:687-95; PMID:24382348; http://dx.doi.org/10.1172/JCI67313
21. L.Corrales, L.H.Glickman, S.M.McWhirter, D.B.Kanne, K.E.Sivick, G.E.Katibah, S.R.Woo, E.Lemmens, T.Banda, J.J.Leong et al. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep. 2015; 11:1018-30; PMID:25959818; http://dx.doi.org/10.1016/j.celrep.2015.04.031
22. E.P.Salerno, W.C.Olson, C.McSkimming, S.Shea, C.L.Slingluff, Jr. T cells in the human metastatic melanoma microenvironment express site-specific homing receptors and retention integrins. Int J Cancer. 2014; 134:563-74; PMID:23873187; http://dx.doi.org/10.1002/ijc.28391
23. G.Erdag, J.T.Schaefer, M.E.Smolkin, D.H.Deacon, S.M.Shea, L.T.Dengel, J.W.Patterson, C.L.Slingluff, Jr. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res. 2012; 72:1070-80; PMID:22266112; http://dx.doi.org/10.1158/0008-5472.CAN-11-3218
24. M.F.D.Mikucki; J.Matsuzaki, ; J.Skitzki, ; N.Gaulin, ; J.Muhitch, ; A.Ku, ; J.Frelinger, ; K.Odunsi, ; T.Gajewski, ; A.Luster, ; S.Evans,. Non-redundant Requirement for CXCR3 Signaling during Tumoricidal T Cell Trafficking across Tumor Vascular Checkpoints. Nat Commun. 2015; in press; PMID:26109379; http://dx.doi.org/10.1038/ncomms8458
25. S.Spranger, R.Bao, T.F.Gajewski. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 2015; PMID:25970248; http://dx.doi.org/10.1038/nature14404
26. M.Bosenberg, V.Muthusamy, D.P.Curley, Z.Wang, C.Hobbs, B.Nelson, C.Nogueira, J.W.Horner, 2nd, R.Depinho, L.Chin. Characterization of melanocyte-specific inducible Cre recombinase transgenic mice. Genesis 2006; 44:262-7; PMID:16676322; http://dx.doi.org/10.1002/dvg.20205
27. W.E.Damsky, D.P.Curley, M.Santhanakrishnan, L.E.Rosenbaum, J.T.Platt, B.E.Gould Rothberg, M.M.Taketo, D.Dankort, D.L.Rimm, M.McMahon et al. β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell. 2011; 20:741-54; PMID:22172720; http://dx.doi.org/10.1016/j.ccr.2011.10.030
28. D.Dankort, D.P.Curley, R.A.Cartlidge, B.Nelson, A.N.Karnezis, W.E.Damsky, Jr., M.J.You, R.A.DePinho, M.McMahon, M.Bosenberg. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet. 2009; 41:544-52; PMID:19282848; http://dx.doi.org/10.1038/ng.356
29. A.F.Cheung, M.J.Dupage, H.K.Dong, J.Chen, T.Jacks. Regulated expression of a tumor-associated antigen reveals multiple levels of T-cell tolerance in a mouse model of lung cancer. Cancer Res. 2008; 68:9459-68; PMID:19010921; http://dx.doi.org/10.1158/0008-5472.CAN-08-2634
30. G.P.Dunn, A.T.Bruce, H.Ikeda, L.J.Old, R.D.Schreiber. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3:991-8; PMID:12407406; http://dx.doi.org/10.1038/ni1102-991
31. T.Wang, G.Niu, M.Kortylewski, L.Burdelya, K.Shain, S.Zhang, R.Bhattacharya, D.Gabrilovich, R.Heller, D.Coppola et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med. 2004; 10:48-54; PMID:14702634; http://dx.doi.org/10.1038/nm976
32. L.Burdelya, M.Kujawski, G.Niu, B.Zhong, T.Wang, S.Zhang, M.Kortylewski, K.Shain, H.Kay, J.Djeu et al. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J Immunol. 2005; 174:3925-31; PMID:15778348; http://dx.doi.org/10.4049/jimmunol.174.7.3925
33. A.Toso, A.Revandkar, D.Di Mitri, I.Guccini, M.Proietti, M.Sarti, S.Pinton, J.Zhang, M.Kalathur, G.Civenni et al. Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity. Cell Rep. 2014; 9:75-89; PMID:25263564; http://dx.doi.org/10.1016/j.celrep.2014.08.044
34. S.Ihara, H.Kida, H.Arase, L.P.Tripathi, Y.A.Chen, T.Kimura, M.Yoshida, Y.Kashiwa, H.Hirata, R.Fukamizu et al. Inhibitory roles of signal transducer and activator of transcription 3 in antitumor immunity during carcinogen-induced lung tumorigenesis. Cancer Res. 2012; 72:2990-9; PMID:22659452; http://dx.doi.org/10.1158/0008-5472.CAN-11-4062
35. W.Xue, L.Zender, C.Miething, R.A.Dickins, E.Hernando, V.Krizhanovsky, C.Cordon-Cardo, S.W.Lowe. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445:656-60; PMID:17251933; http://dx.doi.org/10.1038/nature05529
36. A.Iannello, T.W.Thompson, M.Ardolino, S.W.Lowe, D.H.Raulet. p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. J Exp Med. 2013; 210:2057-69; PMID:24043758; http://dx.doi.org/10.1084/jem.20130783
37. D.Quigley, L.Silwal-Pandit, R.Dannenfelser, A.Langerod, H.K.Vollan, C.Vaske, J.U.Siegel, O.Troyanskaya, S.F.Chin, C.Caldas et al. Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53. Mol Cancer Res. 2015; 13:493-501; PMID:25351767; http://dx.doi.org/10.1158/1541-7786.MCR-14-0387
38. D.S.Basseres, A.S.Baldwin. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene. 2006; 25:6817-30; PMID:17072330; http://dx.doi.org/10.1038/sj.onc.1209942
39. A.S.Baldwin. Regulation of cell death and autophagy by IKK and NF-kappaB: critical mechanisms in immune function and cancer. Immunol Rev. 2012; 246:327-45; PMID:22435564; http://dx.doi.org/10.1111/j.1600-065X.2012.01095.x
40. E.Pikarsky, R.M.Porat, I.Stein, R.Abramovitch, S.Amit, S.Kasem, E.Gutkovich-Pyest, S.Urieli-Shoval, E.Galun, Y.Ben-Neriah. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431:461-6; PMID:15329734; http://dx.doi.org/10.1038/nature02924
41. F.R.Greten, L.Eckmann, T.F.Greten, J.M.Park, Z.W.Li, L.J.Egan, M.F.Kagnoff, M.Karin. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004; 118:285-96; PMID:15294155; http://dx.doi.org/10.1016/j.cell.2004.07.013
42. R.Muthuswamy, E.Berk, B.F.Junecko, H.J.Zeh, A.H.Zureikat, D.Normolle, T.M.Luong, T.A.Reinhart, D.L.Bartlett, P.Kalinski. NF-kappaB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Res. 2012; 72:3735-43; PMID:22593190; http://dx.doi.org/10.1158/0008-5472.CAN-11-4136
43. M.C.Schmid, C.J.Avraamides, H.C.Dippold, I.Franco, P.Foubert, L.G.Ellies, L.M.Acevedo, J.R.Manglicmot, X.Song, W.Wrasidlo et al. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kgamma, a single convergent point promoting tumor inflammation and progression. Cancer Cell. 2011; 19:715-27; PMID:21665146; http://dx.doi.org/10.1016/j.ccr.2011.04.016
44. L.M.Coussens, L.Zitvogel, A.K.Palucka. Neutralizing tumor-promoting chronic inflammation: a magic bullet?. Science 2013; 339:286-91; PMID:23329041; http://dx.doi.org/10.1126/science.1232227
45. V.Bronte, P.J.Murray. Understanding local macrophage phenotypes in disease: modulating macrophage function to treat cancer. Nat Med. 2015; 21:117-9; PMID:25654601; http://dx.doi.org/10.1038/nm.3794
46. E.A.Mittendorf, A.V.Philips, F.Meric-Bernstam, N.Qiao, Y.Wu, S.Harrington, X.Su, Y.Wang, A.M.Gonzalez-Angulo, A.Akcakanat et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014; 2:361-70; PMID:24764583; http://dx.doi.org/10.1158/2326-6066.CIR-13-0127
47. G.Almanzar, S.Schwaiger, B.Jenewein, M.Keller, D.Herndler-Brandstetter, R.Wurzner, D.Schonitzer, B.Grubeck-Loebenstein. Long-term cytomegalovirus infection leads to significant changes in the composition of the CD8+ T-cell repertoire, which may be the basis for an imbalance in the cytokine production profile in elderly persons. J Virol. 2005; 79:3675-83; PMID:15731261; http://dx.doi.org/10.1128/JVI.79.6.3675-3683.2005
48. L.Zitvogel, L.Galluzzi, S.Viaud, M.Vetizou, R.Daillere, M.Merad, G.Kroemer. Cancer and the gut microbiota: an unexpected link. Sci Transl Med. 2015; 7:271ps1; PMID:25609166; http://dx.doi.org/10.1126/scitranslmed.3010473
49. E.Wang, L.Uccellini, F.M.Marincola. A genetic inference on cancer immune responsiveness. Oncoimmunology 2012; 1:520-5; PMID:22754772; http://dx.doi.org/10.4161/onci.19531
50. L.Uccellini, V.De Giorgi, Y.Zhao, B.Tumaini, N.Erdenebileg, M.E.Dudley, S.Tomei, D.Bedognetti, M.L.Ascierto, Q.Liu et al. IRF5 gene polymorphisms in melanoma. J Transl Med. 2012; 10:170; PMID:22909381; http://dx.doi.org/10.1186/1479-5876-10-170
51. D.W.Cescon, B.Haibe-Kains, T.W.Mak. APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. Proc Natl Acad Sci U S A. 2015; 112:2841-6; PMID:25730878; http://dx.doi.org/10.1073/pnas.1424869112